Cours suspendu

Autres langues Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
25,59 ^USD	+0,08%		-.--%	-

17/06	Deciphera Pharmaceuticals administre la première dose dans l'étude pivot de phase 3 INTREPID sur le sapablursen dans la maladie de Vaquez	CI
26/03	Ono Pharmaceutical dépose une demande d'homologation pour le ripretinib au Japon	CI

Autres langues

17/06	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera
26/03	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan
17/02	Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
06/12	Deciphera Pharmaceuticals Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemiaera at the 67th American Society of Hematology Annual Meeting
28/07/25	Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza?? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor
15/02/25	Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Approval of Deciphera's Romvimza?? for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor
11/06/24	Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
11/06/24	Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes
11/06/24	Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index
10/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Biotechnology Index
03/06/24	Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor At the 2024 Asco Annual Meeting and Online Publication in the Lancet
03/06/24	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
10/05/24	Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
02/05/24	DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
30/04/24	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
29/04/24	US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week
29/04/24	Top Midday Gainers
29/04/24	Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical
29/04/24	Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal
29/04/24	Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma
29/04/24	Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal